

CLINICAL TRIALS IN DOWN SYNDROME FOR CO-OCCURRING CONDITIONS ACROSS THE LIFESPAN WORKSHOP

Agenda

Day 1 – May 7, 2020	
8:30 a.m.	NIH Welcome Diana W. Bianchi <i>Eunice Kennedy Shriver</i> National Institute of Child Health and Human Development (NICHD)
	Introduction of Workshop Laurie Ryan, National Institute on Aging (NIA)
	Overview of Workshop Logistics Erika Tarver, NIA
8:40 a.m.	Prenatal Treatment: Clinical Trial of the Future? Diana W. Bianchi, NICHD
9:00 a.m.	Session: Pediatric/Developmental Conditions
9:05 a.m.	 (co-chairs: Priya Kishnani and Steve Abman) Pediatric Cardiology Consideration in Children with Down Syndrome Ashraf Harahsheh, Children's National Health System
9:20 a.m.	 Sleep conditions Role of Sleep for Cognitive Development in Down Syndrome Jamie Edgin, University of Arizona
9:35 a.m.	 Sleep Apnea in Children with Down Syndrome Daniel Combs, University of Arizona
9:50 a.m.	• Take a Breath: Post-Influenza-Like State in Down Syndrome Michael Yeager, University of Colorado Denver
10:05 a.m.	• Infectious Diseases in People with Down Syndrome Andrew Nowalk, University of Pittsburgh
10:25 a.m.	• JAK Inhibition in Down Syndrome: Treating Autoimmunity and Beyond Joaquín Espinosa, University of Colorado Denver
10:45 a.m.	BREAK



11:00 a.m.	 Leukemia in Children with D Clinical Trials Jeffrey Taub, Wayne State United 	own Syndrome: Treading Carefully with niversity
11:15 a.m.	 Central Nervous System Con Down Syndrome & Anna Esbensen, Cin 	
11:30 a.m.	Down Syndrome	tions for Clinical Trials in Children with sity of Illinois at Urbana-Champaign
11:45 a.m. – 12:15 p.m.	LUNCH	
12:15 p.m.	 Communication and Language Speech, language, and Ann P. Kaiser, Vand 	ticulation
12:30 p.m.	with Down syndrom	stening and Speech Perception in Children ne 'own National Research Hospital
12:45 p.m.	Down Syndrome: In Visual Supports for	ologies to Characterize Visual Attending in aplications for Optimizing the Design of Communication annsylvania State University
1:00 p.m. – 1:25 p.m.	Session Q&A	
1:25 p.m.	Overview of Clinical Trials in the Do Priya Kishnani, Duke University	wn Syndrome Population
1:45 p.m. – 3:20 p.m.	Panel: Considerations for Particip Adult Populations Moderator: Priya Kishnani [5-minute presentation per panelist +	ation in Clinical Trials – Pediatric and Q&A]
	Discussants:Frank Stephens (self-advocate)	• Florence Lai (physician)
	• Ben Handen (psychologist)	• David Egan (self-advocate)
	Emily Chesnut	• Kathleen Egan (parent/advocate)
	(parent/advocate)	• Hampus Hillerstrom (parent/advocate)
	• Marilyn Bull (physician)	Donna and Wayne Leigh
	 Michelle Sie Whitten (parent/advocate) 	(parent/advocate)
		Brian Skotko (physician/sibling)



3:20 p.m.	BREAK
	Session: Non-pharmacological/Lifestyle Interventions Session Moderator: Annie Cohen
3:30 p.m.	 Lifestyle and Alzheimer's Disease in Down Syndrome: Physical Activity and Cognitive Stimulation Sigan Hartley, University of Wisconsin – Madison
3:45 p.m.	 Music and Social Engagement: Research and Future Directions for Individuals with Down Syndrome Miriam Lense, Vanderbilt University
4:00 p.m.	Session Q&A
	Session: Adult/Aging Conditions (co-chairs: Annie Cohen and Mike Rafii)
4:15 p.m.	Challenges to Defining Obesity in Down Syndrome Andrea Kelly, Children's Hospital of Philadelphia
4:30 p.m.	 Central Nervous System Conditions Alzheimer's Disease, and other Central Nervous System Disorders Michael Rafii, University of Southern California
4:45 p.m.	 Regression: A Review of Available Literature and Research Gaps Michelle Palumbo, Massachusetts General Hospital
5:00 p.m.	Session Q&A
5:20 p.m.	Adjourn Day 1 of Workshop



Day 2, May 8 9:00 a.m.	Session: Overview of INCLUDE Project funded grants on Clinical Trials (R61/R33) and Clinical Trial Readiness (R21)
	Session Moderator: Laurie Ryan
	R21 – Clinical Trial Readiness
9:05 a.m.	Epigenetic Silencing of Trisomy HSA21 Volney Sheen, Beth Israel Deaconess
9:10 a.m.	• Using fNIRS to Study the Neural Correlates of Executive Function and Sleep Impairment in Down Syndrome Nancy Raitano Lee, Drexel University
9:15 a.m.	• Acceptability and Performance on In-Home Polysomnography in Youth with Down Syndrome Ignacio Tapia, Children's Hospital of Philadelphia
9:20 a.m.	• Measures of Pulmonary Health in Children with Down Syndrome Emily DeBoer, University of Colorado Denver
9:25 a.m.	 Early Risk for ADHD Symptoms in Young Children with Down Syndrome Deborah Fidler, Colorado State University
9:30 a.m.	Bronchus-Associated Lymphoid Tissue: Friend or Foe in Down Syndrome Michael Yeager, University of Colorado Denver
9:35 a.m.	 Down Syndrome, Early Cataracts, Eye Diseases, and Beta-amyloid Conformers Geoffrey Chang, University of California, San Diego
	R61/R33 – Clinical Trials Development
9:40 a.m.	 Medications for Obstructive Sleep Apnea to Improve Cognition in Children with Down Syndrome (MOSAIC DS) Daniel Combs, University of Arizona



9:45 a.m.	 Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome Anna Esbensen, Cincinnati Children's Hospital
9:50 a.m.	• JAK Inhibition in Down Syndrome Joaquín Espinosa, University of Colorado Denver
9:55 a.m.	 Clinical trials to Prevent Alzheimer's Disease in Down Syndrome: Trial Ready Cohort – Down syndrome (TRC-DS) Michael Rafii, University of Southern California
10:00 a.m.	• Positive Airway Pressure for the Treatment of the Obstructive Sleep Apnea Syndrome in Children with Down Syndrome Ignacio Tapia, Children's Hospital of Philadelphia
10:15 a.m.	BREAK
10.1 <i>3 a</i> .m.	
10:30 a.m.	Session: Clinical Trial Infrastructure Session Moderator: Steve Abman
	Session: Clinical Trial Infrastructure
10:30 a.m.	Session: Clinical Trial Infrastructure Session Moderator: Steve Abman • Down Syndrome Patient Registries
10:30 a.m. 10:30 a.m.	 Session: Clinical Trial Infrastructure Session Moderator: Steve Abman Down Syndrome Patient Registries Steve Abman, University of Colorado Denver DS-Connect®
10:30 a.m. 10:30 a.m. 10:45 a.m.	 Session: Clinical Trial Infrastructure Session Moderator: Steve Abman Down Syndrome Patient Registries Steve Abman, University of Colorado Denver DS-Connect® Sujata Bardhan, NICHD PTN-DS: Clinical Pharmacokinetics and Safety Trials in Down Syndrome
10:30 a.m. 10:30 a.m. 10:45 a.m. 11:00 a.m.	 Session: Clinical Trial Infrastructure Session Moderator: Steve Abman Down Syndrome Patient Registries Steve Abman, University of Colorado Denver DS-Connect® Sujata Bardhan, NICHD PTN-DS: Clinical Pharmacokinetics and Safety Trials in Down Syndrome Mara Becker, Duke University Pediatric Heart Network

12:00 p.m. – 12:30 p.m. LUNCH



12:30 p.m.	Session: Recruitment into Clinical Trials Session Moderator: Mike Rafii
12:30 p.m.	• Recruitment of Diverse Populations, Lessons Learned and Implications for Down Syndrome Research Annie Cohen, University of Pittsburgh
12:45 p.m. 1:00 p.m.	 Consent Obtaining Consent into Clinical Trials: State Specific Policies and Requirements Sharon Krinsky-McHale, New York State Institute for Basic Research in Developmental Disabilities Obtaining Consent or Assent Ben Handen, University of Pittsburgh
1:15 p.m.	Sessions Q & A
1:30 p.m.	Report from Break-out Teleconference Sessions
	 Pediatric Issues and Considerations Steve Abman and Priya Kishnani
	Adult Issues and Considerations Annie Cohen and Mike Rafii
2:10 p.m.	Breakout Session Reports Q & A
2:30 p.m.	Closing Remarks Gary H. Gibbons National Heart, Lung and Blood Institute
2:45 p.m.	Adjourn Workshop